Leaflet APREMILAST STADA 10mg+20mg+30mg 10mg / 20mg / 30mg film-coated tablets

Product code:
W70935001
Quantity:
1
Indicated for:
psoriasis; psoriatic arthritis
Route of administration:
oral
Substance:
apremilast (PDE4 inhibitor)
ATC
L04AA32 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants
Apremilast is a medication used in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation by decreasing the production of pro-inflammatory cytokines and increasing levels of anti-inflammatory cytokines.

Apremilast is administered orally in tablet form, usually twice daily. It is often used in patients who do not respond adequately to conventional topical or systemic therapies.

Common side effects include nausea, diarrhea, headache, and weight loss. In rare cases, depression or other mood disorders may occur, requiring careful monitoring.

Apremilast is an important therapeutic option for patients with chronic inflammatory conditions, helping to reduce symptoms and improve their quality of life.

General data about APREMILAST STADA 10mg+20mg+30mg 10mg / 20mg / 30mg

Substance:
apremilast
Date of latest medicines list:
01-04-2025
Product code:
W70935001
Concentration:
10mg / 20mg / 30mg
Pharmaceutical form:
film-coated tablets
Quantity:
1
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
STADA ARZNEIMIITEL AG - GERMANIA
Holder:
STADA ARZNEIMITTEL AG - GERMANIA
Number:
15847/2025/01
Shelf life:
5 years

Concentrations available for apremilast

  • 10mg/20mg/30mg
  • 30mg